DDInter1492 DDInter1435
Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012.
Pexidartinib is a selective tyrosine kinase inhibitor that works by inhibiting the colony-stimulating factor (CSF1)/CSF1 receptor pathway. Pexidartinib was originally developed by Daiichi Sankyo, Inc. and it was approved by the FDA in August 2019 as the first systemic therapy for adult patients with symptomatic tenosynovial giant cell tumor. Tenosynovial giant cell tumor is a rare form of non-malignant tumor that causes the synovium and tendon sheaths to thicken and overgrow, leading to damage in surrounding joint tissue.[A182240,L7901] Debilitating symptoms often follow with tenosynovial giant cell tumors, along with a risk of significant functional limitations and a reduced quality of life in patients. While surgical resection is a current standard of care for tenosynovial giant cell tumor, there are tumor types where surgeries are deemed clinically ineffective with a high risk of lifetime recurrence. Pexidartinib works by blocking the immune responses that are activated in tenosynovial giant cell tumors. In clinical trials, pexidartinib was shown to promote improvements in patient symptoms and functional outcomes in TGCT. Pexidartinib is available in oral formulations and it is commonly marketed as Turalio.
Ponatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nilotinib
Ponatinib {u} (Compound) binds {v} (Gene) RET
Ponatinib {u} (Compound) upregulates {v} (Gene) RAB15
Ponatinib {u} (Compound) downregulates {v} (Gene) ATP6V0B
Ponatinib {u} (Compound) causes {v} (Side Effect) Migraine
Ponatinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ranitidine
Ponatinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sodium citrate
Ponatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vibrio cholerae CVD 103-HgR strain live antigen
Ponatinib {u} may lead to a major life threatening interaction when taken with {v} Ramucirumab
Ponatinib {u} may lead to a major life threatening interaction when taken with {v} Tucatinib
Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib
Ponatinib (Compound) binds RET (Gene)
Ponatinib (Compound) upregulates RAB15 (Gene)
Ponatinib (Compound) downregulates ATP6V0B (Gene)
Ponatinib (Compound) causes Migraine (Side Effect)
Ponatinib may cause a minor interaction that can limit clinical effects when taken with Ranitidine
Ponatinib may cause a minor interaction that can limit clinical effects when taken with Sodium citrate
Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Vibrio cholerae CVD 103-HgR strain live antigen
Ponatinib may lead to a major life threatening interaction when taken with Ramucirumab
Ponatinib may lead to a major life threatening interaction when taken with Tucatinib